Firm News

The Latest News from Lucosky Brookman

Lucosky Brookman is a leader in the representation of small and micro-cap companies. The Firm has led it clients through numerous capital raise transaction and over a dozen uplisting and initial public offering transactions.  Access the latest news about Lucosky Brookman, our clients’ business transactions and industry updates here. 

Lucosky Brookman LLP Successfully Represents Brain Scientific in Closing $5.6 Million Senior Secured Convertible Debenture and Warrant Offering

Lucosky Brookman LLP Successfully Represents Brain Scientific in Closing $5.6 Million Senior Secured Convertible Debenture and Warrant Offering

Lucosky Brookman congratulates its client, Brain Scientific, (OTCQB: BRSF) (the "Company"), a medical technology company with multiple patents…

Read More
Lucosky Brookman LLP Successfully Represents EF Hutton in $16.5 Million Registered Direct Offering of Odyssey Marine Exploration, Inc.

Lucosky Brookman LLP Successfully Represents EF Hutton in $16.5 Million Registered Direct Offering of Odyssey Marine Exploration, Inc.

Lucosky Brookman congratulates its client, EF Hutton, division of Benchmark Investments, LLC, on its successful $16.5 million registered…

Read More
Lucosky Brookman LLP Successfully Represents EF Hutton in $4 Million Offering of TC Biopharm (Holdings) PLC American Depositary Shares (ADS)

Lucosky Brookman LLP Successfully Represents EF Hutton in $4 Million Offering of TC Biopharm (Holdings) PLC American Depositary Shares (ADS)

Lucosky Brookman congratulates its client, EF Hutton, division of Benchmark Investments, LLC, on its successful $4 million underwritten…

Read More
Lucosky Brookman Successfully Represents Aegis Capital Corp. in Pricing of $10 Million Public Offering and Nasdaq Listing of SOBR Safe, Inc.

Lucosky Brookman Successfully Represents Aegis Capital Corp. in Pricing of $10 Million Public Offering and Nasdaq Listing of SOBR Safe, Inc.

Lucosky Brookman LLP congratulates SOBR Safe, Inc. (NASDAQ: SOBR), providers of innovative solutions for alcohol policy management, on its…

Read More
Lucosky Brookman Successfully Represents Modular Medical, Inc. Close $8 Million Registered Direct Offering

Lucosky Brookman Successfully Represents Modular Medical, Inc. Close $8 Million Registered Direct Offering

Lucosky Brookman LLP congratulates its client, Modular Medical, Inc. (NASDAQ: MODD), a development-stage insulin pump company focused on…

Read More
Lucosky Brookman Successfully Represents Vivakor, Inc. Close $8 Million Public Offering and Nasdaq Uplisting

Lucosky Brookman Successfully Represents Vivakor, Inc. Close $8 Million Public Offering and Nasdaq Uplisting

Lucosky Brookman LLP congratulates its client, Vivakor, Inc. (NASDAQ: VIVK), a socially responsible operator, acquirer and developer of clean…

Read More
Lucosky Brookman Successfully Represents Modular Medical, Inc. Close $15 Million Public Offering and Nasdaq Uplisting

Lucosky Brookman Successfully Represents Modular Medical, Inc. Close $15 Million Public Offering and Nasdaq Uplisting

Lucosky Brookman LLP congratulates its client, Modular Medical, Inc. (NASDAQ: MODD), a development-stage insulin pump company focused on…

Read More
Lucosky Brookman LLP Successfully Represents EF Hutton in $16.3 Million Initial Public Offering and Nasdaq Listing of TC Biopharm

Lucosky Brookman LLP Successfully Represents EF Hutton in $16.3 Million Initial Public Offering and Nasdaq Listing of TC Biopharm

Lucosky Brookman congratulates its client, EF Hutton, division of Benchmark Investments, LLC, on its successful $16.3 million initial public…

Read More
Lucosky Brookman Successfully Represents American Rebel Holdings, Inc. in Pricing of $10.5 Million Public Offering and Nasdaq Listing

Lucosky Brookman Successfully Represents American Rebel Holdings, Inc. in Pricing of $10.5 Million Public Offering and Nasdaq Listing

Lucosky Brookman LLP congratulates its client, American Rebel Holdings, Inc. (NASDAQ: AREB; AREBW), a designer and marketer of branded safes…

Read More
Lucosky Brookman Successfully Represents BiondVax Pharmaceuticals Ltd. in Closing of $9.8 million Follow-on Underwritten Offering of ADSs

Lucosky Brookman Successfully Represents BiondVax Pharmaceuticals Ltd. in Closing of $9.8 million Follow-on Underwritten Offering of ADSs

Lucosky Brookman LLP congratulates its client, BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) on its successful closing of an underwritten…

Read More